Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome Clinical Trial
— TopCSPNOfficial title:
Topiramate as a Disease Modifying Therapy for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
| Verified date | October 2023 |
| Source | Virginia Commonwealth University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The TopCSPN trial is a double blinded randomized placebo controlled study of oral topiramate as a potential disease modifying therapy for cryptogenic sensory peripheral neuropathy (CSPN). Patients with CSPN who also have metabolic syndrome (defined by the ATPIII criteria) who do not have an alternative cause for neuropathy will be potentially eligible. The co primary outcome measures are change in the Norfolk Quality of Life - Diabetic Neuropathy (NQOL-DN) Scale and intraepidermal nerve fiber density (IEFND) at the distal thigh. The treatment phase will last 24 months.
| Status | Completed |
| Enrollment | 132 |
| Est. completion date | September 28, 2021 |
| Est. primary completion date | September 28, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 80 Years |
| Eligibility | Inclusion Criteria 1. Age 18-80 2. Diagnosis of confirmed symptomatic distal symmetric peripheral polyneuropathy based on the Toronto consensus criteria for probable neuropathy (the presence of unequivocal signs and symptoms of neuropathy)45. 3. Evidence of symptomatic neuropathy based on a screening visit NQOL-DN score of >9. 4. Metabolic syndrome based on modified ATPIII criteria. Specific criteria require 3 of the following 6 to be present at the screening visit. - Waist circumference >102 cm for men, >88 cm for women - Serum triglycerides of > 150 mg/dl - HDL < 40 mg/dl for men, < 50 mg/dl for women - Those with either a normal HDL or TRG who are taking a lipid lowering medication for this purpose - Blood pressure 130/85 mm Hg or use of anti-hypertension drug - Hyperglycemia based on American Diabetes Association (ADA) criteria at screening based on any one or more of the following: fasting plasma glucose > 100 mg/dL (5.6 mmol/L), 2-hour glucose tolerance test > 140 mg/dL (7.8 mmol/L), or hemoglobin A1c > 5.7% . 5. No current or prior history of therapy with topiramate. 6. If female of child-bearing potential (i.e., not surgically sterile or post-menopausal defined as age > 51 years without menses for = 2 years), negative serum pregnancy test at screening and negative urine pregnancy test at baseline visit. 7. Women of child-bearing potential or men with sexual partners of childbearing potential be willing to use an acceptable method of birth control for the duration of the study and for 12 weeks following completion of study drug therapy. Acceptable methods of birth control include abstinence, oral contraceptives, the contraceptive patch, intra-uterine device, the contraceptive ring, and or barrier contraception such as condoms with spermicide. Exclusion Criteria 1. CSS-PI clinical determination of an alternative cause for peripheral neuropathy (including but not limited to rheumatological disorders, Hepatitis B or C, breast cancer treated with neurotoxic chemotherapy within the past 15 years). All potential subjects will have screening neuropathy labs including assessment for diabetes (Hemoglobin A1c, oral glucose tolerance test), vitamin B12 level, and immunofixation47. 2. Type I diabetes or current use of insulin or use of insulin in the past 3 months. 3. HgA1c > 7.5%. Borderline screening labs can be repeated within two weeks with PPI approval. 4. History of recurrent nephrolithiasis, a single episode of nephrolithiasis within one year prior to screening, or use of ongoing preventative treatment. 5. Family history of a hereditary neuropathy in a first-degree relative. 6. Severe neuropathy: Utah Early Neuropathy Score > 24 at screening 7. Active foot ulceration or a history of a nontraumatic foot amputation. 8. ECG with QTc more than 450 ms in men, or 470 ms in women. 9. Risk of excessive bleeding at the skin biopsy site based on the clinical assessment of the CSS-PI. 10. Chronic corticosteroid use excluding topical or inhaled treatment. 11. Use of a carbonic anhydrase inhibitor (such as acetazolamide) due to risk of nephrolithiasis. 12. Planned bariatric surgery. 13. Use of other weight loss medications. 14. Use of scheduled opiates, or as needed opiate medications more than three times weekly. 15. Use of topical capsaicin products within 16 weeks of screening or at any time on study. 16. Medication change for neuropathy symptoms during the 8 weeks prior to screening; or anticipated change for the duration of study participation. 17. Current use of an intrathecal pain pump or spinal cord stimulator. 18. Screening laboratory creatinine = 2.0 mg/dl. 19. Severe edema, dermatologic or lower extremity condition that would increase risk of skin biopsy. 20. Major depression, bipolar affective disorder, or other mental health disorders that are sufficiently severe to increase adverse event risk or impact neuropathy assessment in the opinion of the responsible site principal investigator. 21. Current suicidal ideation within one year prior to the baseline visit as evidenced by answering "yes" to Questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale (C-SSRS). 22. Ataxia sufficiently severe to represent an unacceptable fall risk in the opinion of the site principal investigator. 23. A serious medical condition expected to dramatically shorten life span or prevent participation. 24. Any clinically significant condition or illness, which, in the opinion of the CSS-PI, would pose a risk to the subject or might confound the study including metabolic acidosis, bone marrow suppression, blood dyscrasias, bleeding disorder, or closed angle glaucoma. 25. History of alcohol or drug abuse within the past two years, or existing neuropathy related to past drug or alcohol abuse. 26. History of malignancy within five years prior to study enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. 27. A history of epilepsy. 28. An inability to understand or cooperate with the procedures of the study. 29. Pregnant, or intending to become pregnant, or breastfeeding. |
| Country | Name | City | State |
|---|---|---|---|
| United States | University of Michigan Neurology Clinical Trials Organization | Ann Arbor | Michigan |
| United States | University of Alabama Birmingham | Birmingham | Alabama |
| United States | Massachusetts General Hospital | Boston | Massachusetts |
| United States | Northwestern University | Chicago | Illinois |
| United States | Ohio State University | Columbus | Ohio |
| United States | UT Southwestern Medical Center | Dallas | Texas |
| United States | University of Iowa | Iowa City | Iowa |
| United States | University of Kansas Medical Center | Kansas City | Kansas |
| United States | University of Miami | Miami | Florida |
| United States | Vanderbilt University Medical Center | Nashville | Tennessee |
| United States | Columbia University Medical Center | New York | New York |
| United States | Eastern Virginia Medical Center | Norfolk | Virginia |
| United States | University of California Irvine | Orange | California |
| United States | University of Pennsylvania | Philadelphia | Pennsylvania |
| United States | Barrow Neurological Institute | Phoenix | Arizona |
| United States | Virginia Commonwealth University | Richmond | Virginia |
| United States | University of Rochester Medical Center | Rochester | New York |
| United States | Washington University School of Medicine | Saint Louis | Missouri |
| United States | University of Utah | Salt Lake City | Utah |
| United States | Wake Forest University Baptist Medical Center | Winston-Salem | North Carolina |
| Lead Sponsor | Collaborator |
|---|---|
| Virginia Commonwealth University | National Institute of Neurological Disorders and Stroke (NINDS), NeuroNEXT Network |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Intraepidermal Nerve Fiber Density (IENFD) | Difference in IENFD change between treatment groups over 96 weeks (fibers/mm) (i.e. the slope of change). A skin biopsy is obtained. The sample is stained for nerve fibers. The rate of change in IENFD in fibers/mm is calculated over the 96 week duration of the study and expressed in change in fibers/mm/year (defined as 52 weeks) over the study period (i.e. the slope of change expressed and change in IENFD in fibers/mm over a 52 week period). | 96 weeks | |
| Primary | Norfolk Quality of Life - Diabetic Neuropathy | Difference in NQOL between treatment groups over 96 weeks. The Norfolk QOL-DN is a validated 47-item, patient-reported outcome measure, sensitive to the different features of diabetic neuropathy (DN) including small fiber, large fiber, and autonomic function. A lower score is better. The range of the score is from -4 to 136. The slope of the change in total Norfolk QOL-DD is calculated as the change in total score/52 weeks (one year) | 96 weeks (expressed as a slope in change of total score/52 weeks) | |
| Secondary | Brief Pain Inventory - Diabetic Neuropathy (BPI-DN) Pain Interference | Pain interference score. Each item is scored from 0-10 with a total possible number of points of 70, higher worse. The range of the score is 0-70. The change in score is expressed as a slope of change in pain interference score/52 weeks (one year) | 96 weeks (expressed as a change in change in pain interference/52weeks) | |
| Secondary | Brief Pain Inventory - Diabetic Neuropathy (BPI-DN) Average Pain Intensity | Average pain severity. Each item is scored 0-10 with a total of 40 possible points, higher is worse. The range of the score is 0-40. The slope of the change in this score is expressed as change/one year (defined as 52 weeks) | 96 weeks (expressed as a slope of change over 52 weeks) | |
| Secondary | Utah Early Neuropathy Scale | The UENS is a validated examination score of neuropathy severity based on a physical examination (Singleton et al 2008). Total score is 42 (minimum 0 and maximum 42). The higher the score, the worse the outcome is. The change in UENS over the 96 week period is expressed as a slope of change in total UENS over one year defined as 52 weeks. | 96 weeks (expressed as a slope of change in total UENS over 52 weeks). | |
| Secondary | Sural Sensory Amplitude (SSA) | Change in SSA measured in microvolts. SSA is measured by electrically stimulating a nerve through the skin and recording the response. A larger value is better. The normal values vary based on age, with a minimum of 0 (absent). Across all ages, the lower limit of normal is 6 microvolts, although the normal cutoff declines with aging. The change in SSA over the 96 week study period is expressed as a slope of change in uV/52 weeks (the 52 week log (mV) change of non-zero values). | 96 weeks (slope of change in mV/52weeks) | |
| Secondary | Peroneal Motor Conduction Velocity (PMCV) | PMCV change. PMCV is measured by electrically stimulating the nerve through the skin at two different locations and measuring how fast the response travels between the two in meters/second. A higher value is better. The slope of the change in PMCV is expressed as change in meters/second/52 weeks (one year). | 96 weeks (expressed as a slope of change in meter/sec over 52 weeks) | |
| Secondary | Body Mass Index (BMI) | BMI change in kg/m2. BMI is a measure of weight relative to height. The slope of the change in BMI over the study was expressed as change in kg/m2/52 weeks. | 96 weeks (slope of change in kg/m2/52 weeks) | |
| Secondary | Hemoglobin A1C | Slope of the Hemoglobin A1C change. A1C is measured in percent. It provides an estimate of how high blood sugar has been over the past three months. A higher value indicates poor diabetic control. | The annual slope of the change in A1C over 96 weeks expressed in change in percent/52 weeks | |
| Secondary | Serum Triglycerides (TRG) | TRG change. TRG are a type of lipid or fat circulating in the blood. A higher value is associated with increased cardiovascular risk. The slope of the change in TRG was calculated as change in mg/dl over 52 weeks (one year). | 96 weeks (slope of change mg/dl over 52 weeks) | |
| Secondary | LDL Cholesterol | LDL change. LDL is "bad" cholesterol, measured in mg/dL. A higher value is associated with elevated cardiovascular risk. A slope of change is calculated change in LDL in mg/dL/52 weeks (one year) | 96 weeks (expressed as a slope of change in mg/dl/52 weeks) | |
| Secondary | HDL Cholesterol | HDL change. HDL is "good cholesterol", measured in mg/dL. A lower value is associated with higher cardiovascular risk. The slope of change is calculated as change in mg/dL/52 weeks (one year) | 96 weeks (expressed as slope of change in mg/dL/52 weeks) |